Dr. Jessie English Resigns from Sensei Biotherapeutics Board Sensei Biotherapeutics (SNSE) has shared an announcement. Dr. Jessie English has announced her resignation from the Board of Directors at Sensei Bi…
Citi sets Sensei Biotherapeutics stock to buy with $4 target https://www.investing.com/news/company-news/citi-sets-sensei-biotherapeutics-stock-to-buy-with-4-target-93CH-3468474
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference | SNSE Stock News Sensei Biotherapeutics to present at Jefferies Global Healthcare Conference on June 6th. Watch live webcast for key insights from CEO John Celebi. Replay available.
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 6, 2024 at 8:30 a.m. ET.
Sensei stock plunges 46% in wake of Phase 1 data Sensei Biotherapeutics (SNSE) shares plunged 46% Friday, the day after the biotech company released data from a Phase 1 study of its oncology drug SNS-101. Read more here.
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? Sensei Biotherapeutics (NASDAQ: SNSE ) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101. SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA.
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity -
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member PARIS--(BUSINESS WIRE)--EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience. The appointment of Dr Motlagh is critical for Egle, as the company.
SNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024 Sensei Biotherapeutics (NASDAQ: SNSE ) just reported results for the first quarter of 2024. Sensei Biotherapeutics reported earnings per share of -32 cents. This was below the analyst estimate for EPS of -27 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post SNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024 appeared first on InvestorPlace .